[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7377 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 7377

    To amend the Federal Food, Drug, and Cosmetic Act to modernize 
             therapeutic equivalence rating determinations.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 4, 2022

 Mr. Curtis (for himself and Ms. Craig) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
    To amend the Federal Food, Drug, and Cosmetic Act to modernize 
             therapeutic equivalence rating determinations.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Modernizing Therapeutic Equivalence 
Rating Determination Act''.

SEC. 2. THERAPEUTIC EQUIVALENCE DETERMINATIONS.

    Section 505(j)(7)(A) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(j)(7)(A)) is amended by adding at the end the following:
    ``(v)(I) The Secretary shall make a determination under clause 
(i)(III)--
            ``(aa) with respect to an application submitted under this 
        subsection, at the time of approval of such application or not 
        later than 30 days after the date of such approval; or
            ``(bb) with respect to an application submitted under 
        subsection (b)(2), at the time of approval of such application 
        or not later than 30 days after the date of such approval, 
        provided that the sponsor requests such a determination in the 
        original application, in a form prescribed by the Secretary.
    ``(II) When the Secretary makes a determination under clause 
(i)(III), the Secretary shall, in revisions made to the list pursuant 
to clause (ii), include such information for such drug.
    ``(III) When the Secretary makes a determination under clause 
(i)(III) with respect to a drug, the Secretary shall, at the same time, 
make such a determination with respect to any other drug--
            ``(aa) whose application under subsection (b)(2) was 
        approved;
            ``(bb) which references the same listed drug as the 
        application for the first drug for which such determination is 
        made; and
            ``(cc) for which there is a citizen petition pending 
        requesting that the Secretary make a determination under clause 
        (i)(III).''.
                                 <all>